Part 5: Myelodysplastic syndromes—Treatment of high-risk disease (2018)
Source: Hematology. Unidade: FM
Subjects: HEMATOLOGIA, PACIENTES, ANEMIA, QUIMIOTERAPIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MAGALHÃES, Silvia Maria Meira et al. Part 5: Myelodysplastic syndromes—Treatment of high-risk disease. Hematology, v. 40, n. 3, p. 278-282, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.htct.2018.05.013. Acesso em: 03 out. 2024.APA
Magalhães, S. M. M., Chauffaille, M. de L. L. F., Velloso, E. D. R. P., Buzzini, R., & Bernardo, W. M. (2018). Part 5: Myelodysplastic syndromes—Treatment of high-risk disease. Hematology, 40( 3), 278-282. doi:10.1016/j.htct.2018.05.013NLM
Magalhães SMM, Chauffaille M de LLF, Velloso EDRP, Buzzini R, Bernardo WM. Part 5: Myelodysplastic syndromes—Treatment of high-risk disease [Internet]. Hematology. 2018 ; 40( 3): 278-282.[citado 2024 out. 03 ] Available from: https://doi.org/10.1016/j.htct.2018.05.013Vancouver
Magalhães SMM, Chauffaille M de LLF, Velloso EDRP, Buzzini R, Bernardo WM. Part 5: Myelodysplastic syndromes—Treatment of high-risk disease [Internet]. Hematology. 2018 ; 40( 3): 278-282.[citado 2024 out. 03 ] Available from: https://doi.org/10.1016/j.htct.2018.05.013
